NantKwest is a clinical-stage immunotherapy company that is focused on utilizing the innate immune system to treat cancer and infectious diseases. The company is a leading producer of clinical dose forms of off-the-shelf natural killer cell therapies, which are designed to destroy cancer and virally-infected cells. NantKwest has conducted multiple phase I and II clinical trials in the United States, Canada, and Europe to test the safety and effectiveness of these activated NK cells. The company aims to transform medicine by bringing novel NK cell-based therapies to routine clinical care, using an integrated and extensive genomics and transcriptomics discovery and development engine, combined with a pipeline of multiple immuno-oncology programs. As a member of the NantWorks ecosystem of companies, NantKwest has a strong foundation in science and innovation to drive its mission forward.
NantKwest, Inc.'s ticker is NK
The company's shares trade on the NASDAQ stock exchange
They are based in Culver City, California
There are 51-200 employees working at NantKwest, Inc.
It is https://nantkwest.com/
NantKwest, Inc. is in the Healthcare sector
NantKwest, Inc. is in the Biotechnology industry
The following five companies are NantKwest, Inc.'s industry peers: